Document is current
Any future updates will be listed below
-
Authors
Gui, Lin
Xie, Zucheng
Qin, Yan
Liu, Peng
Yang, Jianliang
Chen, Xinrui
Li, Zhenyu
Tao, Ran
Shi, Yuankai
-
Funding
Funding for this research was provided by:
Xynomic Pharmaceuticals (Nanjing) Co., Ltd.
- License Information
-
More Information
Article History
Received: 19 April 2024
Accepted: 20 May 2025
First Online: 30 May 2025
Declarations
:
: The study protocol was approved by the ethics committees of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (19–115/1899). The study was conducted in accordance with the Declaration of Helsinki, the principles of the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice Guidelines, and the local regulations. Written informed consent was obtained from all patients before enrollment. This study was registered at ClinicalTrials.gov (NCT04024696).
: Not applicable.
: Ran Tao is an employee of Xynomic Pharmaceuticals (Nanjing) Co., Ltd. Other authors have no conflicts of interest to declare.Other authors have no competing interests to declare.
